Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Abstract The urgent need for new antibacterial agents is well recognized, as the rapid emergence of resistance continues to outpace current drug development efforts. To address this challenge, the Moore and Mankin/Vázquez-Laslop labs are collaborating to advance the development of translation termination inhibitors, a novel antibacterial mechanism observed only in the Class II subset of proline-rich antimicrobial peptides (PrAMPs). Apidaecin (Api) and drosocin (Dro), both Class II PrAMPs, share this unique mechanism despite having distinct sequences and binding modalities. Recently, the Mankin/Vázquez-Laslop lab identified Pdi1, an insect-derived translation termination inhibitor with similarity to Api. This proposal outlines a plan to leverage Pdi1 and the structurally distinct Dro to design and optimize novel hybrid translation termination inhibitors with enhanced potency and metabolic stability. Pdi1’s similarity to Api also provides a framework to investigate the role of secondary structure in this mechanism of action. Notably, Api’s bioactive conformation includes polyproline type II (PPII) features. Incorporating proline derivatives into Pdi1 will constrain the amide bond conformation and provide a systematic approach to study how PPII structure influences the peptide’s antimicrobial activity. The results of this work will be fundamental to the development of FDA-approvable translation termination inhibitors.
Grant Summary
Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $50K for university, nonprofit, healthcare org. Applications are due 2027-07-15 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $50K
2027-07-15
- 1Confirm your organization is eligible for Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors: Frequently Asked Questions
Who is eligible for the Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors?
Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors provide?
Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors provides up to $50K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors deadline?
Applications for Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors are due 2027-07-15 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors?
To apply for Development of Novel Antimicrobial Peptides, Pdi1-Derived Translation Termination Inhibitors, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.